Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

轻度认知障碍和阿尔茨海默病受试者的纵向功能磁共振波谱研究

卷 18, 期 4, 2021

发表于: 08 September, 2021

页: [335 - 346] 页: 12

弟呕挨: 10.2174/1567205018666210708145924

价格: $65

摘要

背景：在健忘性轻度认知障碍 (aMCI) 和阿尔茨海默病 (AD) 受试者中，功能刺激期间脑代谢物的纵向变化是未知的。

目的：本研究旨在使用质子磁共振波谱 (1H MRS) 评估认知正常 (CN)、aMCI 和 AD 受试者在记忆任务期间响应治疗的脑代谢物的纵向变化。

方法：我们在面部姓名关联任务中从 28 名 CN 老年人、16 名 aMCI 和 12 名 AD 受试者获得了功能磁共振波谱 (fMRS) 数据。我们在相隔 8 个月的时间内测量了 24 个月的 fMRS 代谢物比率，确定了代谢物的时间变化，并评估了在三种不同条件下（基础、新颖、重复）下三组之间的差异。

结果：三个受试者组和三个时间点的比较结果表明，tNAA/tCho 和 tCr/tCho 在三个受试者组中在三种条件中的任何一种中均具有统计学意义。每种条件下代谢物的动态时间变化测量表明，在 AD 组的新条件下，第三次访问时的 Glx/tCho 和 Glu/tCho 水平与第一次访问时相比显着增加。

结论：我们发现 aMCI 和 AD 受试者的 tNAA/tCho 和 tCr/tCho 随着疾病严重程度的增加而下降，在 CN 中最高，在 AD 中最低。服用乙酰胆碱酯酶抑制剂后，AD 受试者的 Glx/tCho 水平暂时增加。因此，Glx 可能适合证明治疗后的功能恢复。

关键词: 纵向研究、功能磁共振波谱、阿尔茨海默病、轻度认知障碍、谷氨酰胺和谷氨酸复合物 (Glx)、总 N-乙酰天冬氨酸 (tNAA)。

« Previous Next »
[1]
Graff-Radford J, Kantarci K. Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatr Dis Treat 2013; 9: 687-96.
[PMID: 23696705]
[2]
Mandal K, Pravat . Magnetic Resonance Spectroscopy (MRS) and its application in Alzheimer’s disease. Concepts Magnetic Resonance Part A 2007; 30A(1): 40-64.
[http://dx.doi.org/10.1002/cmr.a.20072]
[3]
Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging. Magn Reson Med 1999; 41(2): 276-84.
[http://dx.doi.org/10.1002/(SICI)1522-2594(199902)41:2<276::AID-MRM10>3.0.CO;2-8] [PMID: 10080274]
[4]
Criteria for the clinical diagnosis of Alzheimer’s disease. Excerpts from the NINCDS-ADRDA work group report. J Am Geriatr Soc 1985; 33(1): 2-3.
[http://dx.doi.org/10.1111/j.1532-5415.1985.tb02850.x] [PMID: 3965552]
[5]
Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 2009; 30(3): 353-63.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.07.005] [PMID: 17719145]
[6]
Shulman RG, Hyder F, Rothman DL. Biophysical basis of brain activity: Implications for neuroimaging. Q Rev Biophys 2002; 35(3): 287-325.
[http://dx.doi.org/10.1017/S0033583502003803] [PMID: 12599751]
[7]
Clare L, Wilson BA, Carter G, Roth I, Hodges JR. Relearning face name associations in early Alzheimer’s disease. Neuropsychology 2002; 16(4): 538-47.
[http://dx.doi.org/10.1037/0894-4105.16.4.538] [PMID: 12382992]
[8]
Sperling RA, Laviolette PS, O’Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63(2): 178-88.
[http://dx.doi.org/10.1016/j.neuron.2009.07.003] [PMID: 19640477]
[9]
Jahng GH, Oh J, Lee DW, et al. Glutamine and glutamate complex, as measured by functional magnetic resonance spectroscopy, alters during face-name association task in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2016; 52(1): 145-59.
[http://dx.doi.org/10.3233/JAD-150877] [PMID: 27060946]
[10]
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58(12): 1985-92.
[http://dx.doi.org/10.1001/archneur.58.12.1985] [PMID: 11735772]
[11]
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56(3): 303-8.
[http://dx.doi.org/10.1001/archneur.56.3.303] [PMID: 10190820]
[12]
Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease: A clinicopathologic study of 57 cases. Neurology 1988; 38(3): 359-64.
[http://dx.doi.org/10.1212/WNL.38.3.359] [PMID: 3347338]
[13]
Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCmodel. NMR Biomed 2001; 14(4): 260-4.
[http://dx.doi.org/10.1002/nbm.698] [PMID: 11410943]
[14]
Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68(9): 785-94.
[http://dx.doi.org/10.1016/j.biopsych.2010.06.016] [PMID: 20728076]
[15]
Huang Z, Davis HH IV, Yue Q, et al. Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental imagery: A combined functional mrs and fMRI study. Hum Brain Mapp 2015; 36(8): 3204-12.
[http://dx.doi.org/10.1002/hbm.22841] [PMID: 26059006]
[16]
Cleve M, Gussew A, Reichenbach JR. In vivo detection of acute pain-induced changes of GABA+ and Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. Neuroimage 2015; 105: 67-75.
[http://dx.doi.org/10.1016/j.neuroimage.2014.10.042] [PMID: 25462698]
[17]
Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(1): 104-10.
[http://dx.doi.org/10.1016/j.pnpbp.2009.10.007] [PMID: 19833161]
[18]
Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci 2012; 11: 199-251.
[http://dx.doi.org/10.1007/7854_2011_197] [PMID: 22294088]
[19]
Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 2003; 160(11): 2003-11.
[http://dx.doi.org/10.1176/appi.ajp.160.11.2003] [PMID: 14594748]
[20]
Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006; 67(3): 528-30.
[http://dx.doi.org/10.1212/01.wnl.0000228218.68451.31] [PMID: 16894124]

Rights & Permissions Print Cite
Article Metrics
46
1
© 2024 Bentham Science Publishers | Privacy Policy